These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23186973)

  • 1. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes.
    Lane WS; Weinrib SL; Rappaport JM; Hale CB; Farmer LK; Lane RS
    Endocr Pract; 2013; 19(2):196-201. PubMed ID: 23186973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. U-500: a convenient insulin for a convenience food nation.
    Tannock LR
    Endocr Pract; 2013; 19(2):194-5. PubMed ID: 23598533
    [No Abstract]   [Full Text] [Related]  

  • 3. TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.
    Hood RC; Arakaki RF; Wysham C; Li YG; Settles JA; Jackson JA
    Endocr Pract; 2015 Jul; 21(7):782-93. PubMed ID: 25813411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital.
    Kedia R; Desouza C; Smith LM; Shivaswamy V
    J Diabetes Complications; 2017 May; 31(5):874-879. PubMed ID: 28274680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
    Munshi MN; Gill J; Chao J; Nikonova EV; Patel M
    Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved glycemic control and acute complications among children with type 1 diabetes mellitus in Moshi, Tanzania.
    Mukama LJ; Moran A; Nyindo M; Philemon R; Msuya L
    Pediatr Diabetes; 2013 May; 14(3):211-6. PubMed ID: 23350587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Experience with U-500 Regular Insulin by Multiple Daily Injections and Continuous Subcutaneous Insulin Infusion.
    Meade LT; Tart RC; Nuzum D
    Diabetes Technol Ther; 2017 Apr; 19(4):220-225. PubMed ID: 28249123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance.
    Lane WS; Weinrib SL; Rappaport JM; Przestrzelski T
    Endocr Pract; 2010; 16(5):778-84. PubMed ID: 20350913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of glycemic control using U-500 insulin.
    Dailey AM; Gibert JA; Tannock LR
    Diabetes Res Clin Pract; 2012 Mar; 95(3):340-4. PubMed ID: 22088791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.
    Mari A; Rosenstock J; Ma X; Li YG; Jackson JA
    Endocr Pract; 2015 Dec; 21(12):1344-52. PubMed ID: 26307903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study.
    Giménez M; Lara M; Conget I
    Diabetes Technol Ther; 2010 Jul; 12(7):517-21. PubMed ID: 20597825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes.
    Summers JC; Briganti EM; Fitzgerald ZA; Lambers LNJ; Cohen ND
    Diabetes Technol Ther; 2019 Aug; 21(8):423-429. PubMed ID: 31180239
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen® among US veterans with type 2 diabetes mellitus.
    Chen J; Borra S; Fan L; Huang A; Patel D; Juneja R
    J Diabetes Complications; 2021 Oct; 35(10):107995. PubMed ID: 34364779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series.
    Knee TS; Seidensticker DF; Walton JL; Solberg LM; Lasseter DH
    Endocr Pract; 2003; 9(3):181-6. PubMed ID: 12917058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes.
    Bulchandani DG; Konrady T; Hamburg MS
    Endocr Pract; 2007; 13(7):721-5. PubMed ID: 18194928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control.
    Choi SB; Lee JH; Lee JH; Kim S; Han SD; Kim IH; Noh YH
    Diabetes Metab Res Rev; 2013 Sep; 29(6):473-82. PubMed ID: 23592489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
    Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
    Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained metabolic control and low rates of severe hypoglycaemic episodes in preschool diabetic children treated with continuous subcutaneous insulin infusion.
    Pańkowska E; Szypowska A; Lipka M; Skórka A
    Acta Paediatr; 2007 Jun; 96(6):881-4. PubMed ID: 17537017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.